Smith Salley & Associates Has Increased Its Maxim Integrated Prods (MXIM) Stake; Integra Lifesciences Holdings (IART) Has 0.98 Sentiment

May 24, 2018 - By Clifton Ray

Maxim Integrated Products, Inc. (NASDAQ:MXIM) Logo

Smith Salley & Associates increased Maxim Integrated Prods Inc (MXIM) stake by 93% reported in 2017Q4 SEC filing. Smith Salley & Associates acquired 24,862 shares as Maxim Integrated Prods Inc (MXIM)’s stock rose 11.78%. The Smith Salley & Associates holds 51,596 shares with $2.70M value, up from 26,734 last quarter. Maxim Integrated Prods Inc now has $16.45B valuation. The stock decreased 0.19% or $0.11 during the last trading session, reaching $58.82. About 2.16M shares traded. Maxim Integrated Products, Inc. (NASDAQ:MXIM) has risen 31.76% since May 24, 2017 and is uptrending. It has outperformed by 20.21% the S&P500.

Integra Lifesciences Holdings Corp (IART) investors sentiment decreased to 0.98 in 2017 Q4. It’s down -0.31, from 1.29 in 2017Q3. The ratio worsened, as 88 funds increased or opened new holdings, while 90 reduced and sold their holdings in Integra Lifesciences Holdings Corp. The funds in our database now have: 70.22 million shares, up from 68.21 million shares in 2017Q3. Also, the number of funds holding Integra Lifesciences Holdings Corp in top ten holdings was flat from 2 to 2 for the same number . Sold All: 20 Reduced: 70 Increased: 65 New Position: 23.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has market cap of $5.62 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies. It has a 77.99 P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

More notable recent Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were published by: Globenewswire.com which released: “Integra LifeSciences to Present at Healthcare Conferences in June 2018” on May 23, 2018, also Globenewswire.com with their article: “Integra LifeSciences Prices Public Offering of Common Stock” published on May 09, 2018, Globenewswire.com published: “Integra LifeSciences Reports First Quarter 2018 Financial Results” on April 25, 2018. More interesting news about Integra LifeSciences Holdings Corporation (NASDAQ:IART) were released by: Globenewswire.com and their article: “Analysis: Positioning to Benefit within Webster Financial, Integra LifeSciences, OSI, Tivity Health, LCI Industries, and …” published on May 17, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” with publication date: May 08, 2018.

Sector Gamma As holds 4.08% of its portfolio in Integra LifeSciences Holdings Corporation for 506,630 shares. Broadfin Capital Llc owns 330,600 shares or 2.59% of their US portfolio. Moreover, Champlain Investment Partners Llc has 2.52% invested in the company for 4.65 million shares. The California-based Falcon Point Capital Llc has invested 2.09% in the stock. Tributary Capital Management Llc, a Colorado-based fund reported 361,795 shares.

Analysts await Integra LifeSciences Holdings Corporation (NASDAQ:IART) to report earnings on July, 25. They expect $0.60 earnings per share, up 33.33% or $0.15 from last year’s $0.45 per share. IART’s profit will be $52.73M for 26.65 P/E if the $0.60 EPS becomes a reality. After $0.58 actual earnings per share reported by Integra LifeSciences Holdings Corporation for the previous quarter, Wall Street now forecasts 3.45% EPS growth.

The stock decreased 0.06% or $0.04 during the last trading session, reaching $63.95. About 418,357 shares traded. Integra LifeSciences Holdings Corporation (IART) has risen 29.35% since May 24, 2017 and is uptrending. It has outperformed by 17.80% the S&P500.

Smith Salley & Associates decreased Select Sector Spdr Tr (XLP) stake by 7,555 shares to 11,231 valued at $639,000 in 2017Q4. It also reduced Select Sector Spdr Tr (XLI) stake by 9,620 shares and now owns 14,951 shares. Mdu Res Group Inc (NYSE:MDU) was reduced too.

More recent Maxim Integrated Products, Inc. (NASDAQ:MXIM) news were published by: Seekingalpha.com which released: “Maxim Integrated Products (MXIM) Q3 2018 Results – Earnings Call Transcript” on April 27, 2018. Also Prnewswire.com published the news titled: “Popularity of Third Party Manufacturing and Logistics Services are Set to Grow” on May 23, 2018. Prnewswire.com‘s news article titled: “Maxim’s Compact Synchronous Buck Converters Provide Industry’s Lowest EMI Performance for Automotive …” with publication date: May 23, 2018 was also an interesting one.

Since December 18, 2017, it had 0 insider buys, and 28 sales for $18.64 million activity. $25,304 worth of Maxim Integrated Products, Inc. (NASDAQ:MXIM) shares were sold by Wright Mary Ann. Shares for $1.56 million were sold by KIDDOO BRUCE E. $191,249 worth of Maxim Integrated Products, Inc. (NASDAQ:MXIM) was sold by NEIL CHRISTOPHER J on Tuesday, May 1. 5,000 shares were sold by BRONSON JOSEPH R, worth $270,407 on Tuesday, May 1. Shares for $335,303 were sold by Grady Robert Edward. $106,000 worth of Maxim Integrated Products, Inc. (NASDAQ:MXIM) was sold by DOLUCA TUNC. Preeshl Bryan sold $221,227 worth of stock or 3,607 shares.

Maxim Integrated Products, Inc. (NASDAQ:MXIM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>